Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

NCT02483585 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

577

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Erenumab
DRUG: Placebo

Sponsor

Amgen